Treating cirrhotic hypoproteinemia by PHGF, wujibaifeng pill combined with salviate milttiorrhize
-
摘要: 目的观察促肝细胞生长素、乌鸡白凤丸、丹参注射液联合对肝硬化低蛋白血症的疗效及安全性。方法选择68例有低蛋白血症的肝硬化患者随机分为治疗组(36例)和对照组(32例),在常规护肝治疗基础上,对照组给予丹参注射液静脉滴注,治疗组在对照组的基础上加用促肝细胞生长素(PHGF)静滴,乌鸡白凤丸口服,疗程为60天。分别观察治疗前、治疗后30天、60天及治疗结束后30天的患者的主要症状、肝功能、凝血功能的改善情况及不良反应。结果治疗后治疗组较对照组各项症状均有显著改善(P<0.05,P<0.01),治疗组总有效率(83.3%)明显高于对照组(53.1%)(P<0.01),治疗组AST、ALT及TBil较对照组显著降低、TP、ALB及凝血酶原活动度(PTA)较对照组显著升高(P<0.05,P<0.01),治疗过程中均未发现明显不良反应。结论PHGF、乌鸡白凤丸、复方丹参注射液联合治疗肝硬化低蛋白血症有较好的疗效和安全性。Abstract: Objective To observe the therapeutic effect and security of PHGF, wujibaifeng pill combined with salviate milttiorrhize on the cirrhotic hypoproteinemia.Methods 68 patients with cirrhotic hypoproteinemia were randomly divided into treatment group (n=36) and control group (n=32) .The control group were treated with salviate milttiorrhize by intravenous drip on the basis of routine treatment, while the treatment group were given PHGF by intravenous drip and wujibaifeng pill by orally taken on the basis of control group, each for a treatment course of 60 days.The clinical data including main symptoms, hepatic function and blood coagulation tests were monitored before therapy and on the 30th and 60th days of therapy, and the adverse effects were also monitored after therapy.Results ymptoms of the treatment group improved better than those of the control group (P < 0.05, P < 0.01) .Total effective rates of the treatment group (83.3% ) was higher than that of the control group (53.1% ) (P < 0.01) .The level of aspartate transaminase (AST) , alanine transaminase (ALT) , total bilirubin (TBil) were lower and the level of plasma total protein (TP) , albumin (ALB) , prothrombin active (PTA) were higher in the treatment group than the control group (P <0.05, P <0.01) .No remarkable adverse effects in treatment were observed.Conclusion PHGF, wujibaifeng pill combined with salviate milttiorrhize is effective and safe in the treatment of cirrhotic hypoproteinemia.
-
[1] 上海市复方支链氨基酸颗粒剂疗效观察协作组.复方支链氨基酸颗粒剂治疗肝硬化低蛋白血症多中心临床观察[J].中华消化杂志, 2001, 21 (2) ∶102-104. [2]中华医学会.病毒性肝炎防治方案[J].中华肝脏杂志, 2000, 8 (6) ∶324-329. [3]孙桂华, 孙大勇.用生长激素治疗肝硬化低蛋白质血症疗效观察[J].肠外与肠内营养, 2006, 13 (1) ∶19-21. [4]王宝恩, 张定凤.现代肝脏病学[M].北京:科学出版社, 2003∶534-559. [5]于岩岩, 斯崇文, 曾争, 等.促肝细胞生长素治疗重型肝炎及慢性重度肝炎的临床研究[J].中华传染病杂志, 2003, 21 (1) ∶54-56. [6]Phaneuf D, Chen SJ, Wilson JM.Intravenous injection of an adeno-virus encoding hepatocyte growth factor results in liver growth and has a protective effect against apoptosis[J].Mol Med, 2000, 6 (2) ∶96-103. [7]李小芹, 贺蓉, 周爱香, 等.乌鸡白凤口服液及丸剂对中毒性肝损伤影响的比较[J].中药药理与临床, 2000, 16 (4) ∶1-3. [8]王艳霞, 张玉斗.乌鸡白凤丸在妇科以外的临床应用[J].中成药, 2008, 30 (2) ∶251-254. [9]姜慧敏, 田明涛, 李萍, 等.促肝细胞生长素和丹参联合穴位注射治疗肝炎肝纤维化的临床研究[J].中西医结合肝病杂志, 2008, 18 (1) ∶18-20.
本文二维码
计量
- 文章访问数: 3159
- HTML全文浏览量: 12
- PDF下载量: 920
- 被引次数: 0